novo nordisk amycretin - Search News

Novo Nordisk, amycretin

Novo Nordisk next-gen shot shows 22% weight loss in early results

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.

Hosted on MSN · 6h

Novo Nordisk shares pop on early-stage weight loss drug trial results

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

YAHOO!Finance · 12h

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,

Novo Nordisk’s next-generation obesity treatment shows promise in early study

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

9hon MSN

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

ncbiotech.org2d

IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results